|Denaro||0,00 x 2200|
|Lettera||0,00 x 800|
|Min-Max giorno||149,46 - 152,68|
|Intervallo di 52 settimane||101,36 - 170,75|
|Beta (5 anni mensile)||0,18|
|Rapporto PE (ttm)||24,79|
|Prossima data utili||27 ott 2020|
|Rendimento e dividendo (forward)||2,96 (1,96%)|
|Data ex dividendo||13 ago 2020|
|Stima target 1A||166,64|
Eli Lilly said that its experimental antibody, LY-CoV555, reduced rate of hospitalization for patients with mild or moderate symptoms of COVID-19, sending its shares up about 2% on Wednesday.
Eli Lilly and Company’s price target was raised to $176 from $157 with ‘Overweight’ stock rating, according to Morgan Stanley equity analyst David Risinger, who also said that they are bullish on prospects for Phase 3 diabetes asset tirzepatide and shares offer Alzheimer’s optionality.